PDF(Pubmed)
Abstract：
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is an aggressive hepatic cancer that has characteristics of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). For resectable disease, liver resection is the preferred first treatment option. As for the advanced or metastatic setting, and due to its rarity, there is still no consensus on which is the optimal systemic treatment. As such, regimens used in both HCC and CC have often been used as first-line treatment options. We report a case of a male patient in his 50s, diagnosed with a cHCC-CC with lymph node and adrenal metastasis, with an extensive portal vein tumour thrombosis, that started treatment with a multikinase inhibitor - lenvatinib.
摘要：
联合肝细胞胆管癌（cHCC-CC）是一种侵袭性肝癌，具有肝细胞癌（HCC）和胆管癌（CC）的特征。对于可切除的疾病，肝切除术是首选的第一治疗选择。至于高级或转移性设置，由于它的稀有性,对于哪一种是最佳的全身治疗仍未达成共识.因此，用于HCC和CC的方案通常被用作一线治疗选择。我们报道了一个50多岁的男性病人，诊断为具有淋巴结和肾上腺转移的cHCC-CC，广泛的门静脉肿瘤血栓形成，开始使用多激酶抑制剂-lenvatinib治疗。
